PACE study: Pharmacoeconomics of Anemia in Cancer Evaluation study

Launay-Vacher V[1,2], Deray G[1,2], Brocard F[3], Leuleu X[4], Frikha A[5], Legouffe E[6], Eche-Gass A[7], Miglianico L[8], Agape P[9], Loppinet E[10], Salmeron G[11], Beuzeboc P[12], Zambrowski JJ[13], Scotté F[14]

1) Service ICAR, GH Pitié-Salpêtrière, Paris ; 2) Néphrologie, GH Pitié-Salpêtrière, Paris ; 3) Oncologie, Centre d'Oncologie de Gentilly, Nancy ; 4) Hématologie, CHU de Poitiers, Poitiers ; 5) Oncologie, Polyclinique Maymard, Bastia ; 6) Hématologie, Clinique Valdegour, Nîmes ; 7) Oncologie, Institut Claudius Regaud, Toulouse ; 8) Oncologie, CHP Saint-Grégoire, Rennes ; 9) Hématologie, Institut René Gauducheau, Saint-Herblain ; 10) Hématologie, Hôpital Belle Isle, Metz ; 11) Hématologie, CHI Poissy/Saint-Germain-en-Laye ; 12) Oncologie, Institut Curie, Paris ; 13) Economie de la santé, Medsys, Neuilly sur Seine; 14) Unité de Soins de Support, Oncologie, Hôpital Européen Georges Pompidou, Paris

INTRODUCTION

- Chemotherapy-induced Anemia (CIA) is common in cancer patients.
- It may impact survival, outcomes and contributes to fatigue.
- The treatment includes iron supplementation, blood transfusions (BT) and erythropoiesis stimulating agents (ESA).
- Many studies compared the clinical aspects of CIA treatments in terms of survival, quality of life, safety, and efficacy. However, very few data are available on the pharmacoeconomic aspects of these treatments.
- Especially, the costs of blood transfusions is barely unknown, and difficult to estimate.

OBJECTIVES & CHOICE OF ESA

The PACE study aims at evaluating the costs of CIA treatments by ESA and BT. This first phase of the study will focus on BT and epoetin beta treatments.

Epoetin beta was chosen among ASE for the following reasons:

1) Choice of the coordinator to limit at one ESA, for practical, logistical, and costs reasons (since the PACE study is NOT sponsored by any body and self-financed by Service ICAR.
2) Original ESA and not a biosimilar ESA since in France, prices of Biosimilars may vary quite a lot on a time-period = Exclusion of biosimilar ESAs.
3) Original ESA for which NO biosimilar is available on the French market, in order to avoid potential substitutions => Exclusion of epoetin alpha.
4) Choice of a short-acting ESA => Exclusion of darbepoetin alpha.

Epoetin bêta is the ESA used in the PACE study

METHODS & (expected) RESULTS

PACE is a prospective, multicentric, observational study conducted by Service ICAR, an academic research organization.

The study is neither supported, nor funded by any pharmaceutical firm or health authority.

It is planned to include 400 anemic cancer patients (non-myeloid) treated with blood transfusions or epoetin for chemotherapy-induced anemia.

A pharmacoeconomic evaluation will be performed based on a patient questionnaire to determine all resources involved in the treatment, matched with clinical data collected by Service ICAR.

The Quality of Life (QoL)will also be measured (EORTC-QLQ-C30), in each patient included.

Expected results: The PACE study will 1) estimate the actual costs of BT in the management of CIA, 2) compare the costs of CIA treatment between BT and epoetin-beta, and 3) compare the impact of treatments on QoL.

Enrollement update

As of June 10th, 2017:

- 23 centers participate in the PACE study
- 14 have already included at least one patient
- A total of 111 patients have been included to date
  - 89 epoetin bêta
  - 12 blood transfusions
  - 10 awaiting data collection

REFERENCES

Participating centers *(at time of abstrat submission)*: Oncologie, Centre d'Oncologie de Gentilly, Nancy ; 4) Hématologie, CHU de Poitiers, Poitiers ; 5) Oncologie, Polyclinique Maymard, Bastia ; 6) Hématologie, Clinique Valdegour, Nîmes ; 7) Oncologie, Institut Claudius Regaud, Toulouse ; 8) Oncologie, CHP Saint-Grégoire, Rennes ; 9) Hématologie, Institut René Gauducheau, Saint-Herblain ; 10) Hématologie, Hôpital Belle Isle, Metz ; 11) Hématologie, CHI Poissy/Saint-Germain-en-Laye ; 12) Oncologie, Institut Curie, Paris ; 13) Economie de la santé, Medsys, Neuilly sur Seine; 14) Unité de Soins de Support, Oncologie, Hôpital Européen Georges Pompidou, Paris

ICAR
Information Conseil Adaptation Rénale